Characteristics and recurrence of pterygium in Saudi Arabia: a single center study with a long follow-up

Waleed Alsarhani1,2*, Saeed Alshahrani3, Mahmood Showail4, Nawaf Alhabdan3, Osama Alsumari3, Abdullah Almalki3, Abdulaziz Alsarhani5, Adel Alluhaian6,7 and Bader Alqahtani2,8

Abstract

Background: This study described the clinical features of patients with pterygium and analyzed the recurrence rate of conjunctival autografting alone, conjunctival autografting combined with intraoperative mitomycin C, and amniotic membrane grafting.

Methods: A retrospective cohort study of primary pterygium was conducted between January 2017 and February 2020. Factors associated with pterygium severity and recurrence were analyzed by univariate analysis and logistic regression models.

Results: The study included 292 patients with an average age of 53.3 ± 14.1 years, while the number of operated cases was 94. Pterygia involving the cornea were observed in 55 % of the cases. The overall rate of recurrence for the three procedures was 17 %. The average time of recurrence was 14.2 ± 11.9 months, with 37 % of the recurrences occurring after the first year. The only factor associated with a significant risk of recurrence was dry eye disease in both univariate (p = 0.021) and multivariate analysis (p = 0.026). The recurrence rates following conjunctival autografting with and without mitomycin C were 15.6 and 15.8 %, respectively. The recurrence rate following the amniotic membrane graft was twofold (OR= 2.02) (27 %) that following the conjunctival autograft (15.8 %).

Conclusions: The only factor associated with the recurrence of pterygium was dry eye disease. More than one-third of recurrences developed after the first year, which stresses the importance of a long follow-up. The recurrence rate in our study following conjunctival graft was slightly higher compared to the literature mainly due to differences in study areas, populations, and follow-up periods.

Keywords: Pterygium, Conjunctiva, Recurrence

Background

A pterygium is a wing-shaped fibrovascular tissue extending from the bulbar conjunctiva into the cornea [1]. While pterygium can be asymptomatic, patients may complain of tearing, foreign body sensation or redness. When a pterygium enlarges and encroaches on the cornea, visual disturbance may result from astigmatism, direct visual axis obscuration, or even diplopia caused by limited extraocular motility [2]. The etiology of pterygium is multifactorial; nonetheless, increased ultraviolet (UV) light exposure is the most likely pathogenetic factor for disease development. UV light exposure results in oxidative stress and the release of cytokines and growth factors,
eventually inducing cellular proliferation [3, 4]. This also explains why lower geographic latitude, outdoor activity, and living in rural areas and countries close to the equator are associated with an increased prevalence of pterygium [5, 6]. The worldwide prevalence of pterygium was reported in two meta-analyses performed in 2013 and 2018 and was found to be 10.2 and 12%, respectively [5, 7]. Despite the fact that dry weather and dusty conditions may increase the risk of pterygium, only one study has been published on the pterygium prevalence in Saudi Arabia. That study was conducted in the Eastern Province, and the prevalence was found to be as low as 0.07% [8]. However, this prevalence may be underestimated since only advanced and operable cases were included in the study. The study did not investigate pterygium management and recurrence rates of different surgical interventions.

Surgical intervention for pterygium has evolved over the past several years. Nevertheless, recurrence remains a continuous problem in every single described procedure. Previously, excision and leaving a bare sclera was the only surgical method, but this ended with recurrence in up to 88% of the cases [9]. Multiple procedures have been described to excise pterygium, including mitomycin C injection, conjunctival autografting, amniotic membrane transplantation and beta irradiation [10]. Mitomycin C, which reduces the recurrence rate compared to a bare sclera, may cause necrotizing scleritis, scleral ulceration, endothelial cell loss and corneal edema [11–13]. The procedure of choice should provide the least recurrence with a low complication rate. Race may increase the risk of recurrence, with a study showing higher recurrence rates among Hispanic and black patients [14]. Therefore, conclusions drawn from studies conducted elsewhere cannot be applied to our population. Moreover, Riyadh is known for its dusty weather, another risk elsewhere cannot be applied to our population. More-
burr was applied to smooth the involved part of the cornea. Then, attention was shifted to the superior bulbar conjunctiva, and the matching size of the conjunctiva was marked and then inflated via the injection of lidocaine 1% and epinephrine. Then, the marked area was dissected easily using forceps and Westcott scissors and was moved carefully to cover the bare sclera. The conjunctival autograft was finally sutured with 8−0 Vicryl sutures or occasionally with the aid of fibrin glue (Tissee). If intraoperative mitomycin C was used, a low dose of 0.2 mg/ml (0.02 %) was applied for 1 min. Every pterygium specimen was submitted to the pathology laboratory to confirm the diagnosis.

Amniotic membrane grafting

The surgery started with subconjunctival injection of lidocaine 1% and epinephrine with a 30-gauge needle to achieve anesthesia and hemostasis. Using forceps and Westcott scissors, the pterygium was excised from the periphery towards the limbus. Afterward, a diamond burr was applied to smooth the involved part of the cornea. The amniotic membrane graft was cut into the appropriate size and then sutured to cover the conjunctival defect using Vicryl 8−0 sutures. Each pterygium specimen was submitted to the pathology lab to confirm the diagnosis.

Postoperative period

Tobramycin-dexamethasone ointment twice a day for 2 weeks along with tapering topical steroid drops for 4 weeks was prescribed. Patients were given frequent follow-up appointments in the clinic and were instructed to visit the emergency room if needed.

Statistical analysis

Chi square and independent t tests were applied to analyze the demographic characteristics of our patients. Categorical variables of various eye conditions are presented as proportions, and numerical variables are presented as means and standard deviations. Binary logistic regression was used to investigate factors associated with postoperative recurrence and corneal involvement, and odds ratios with 95% confidence intervals (CIs) were calculated. Multiple logistic regression analysis was performed to adjust for age and gender. The level of significance in this study was set at 0.05.

Results

Baseline clinical characteristics

The study included 292 patients with primary pterygium and an average age of 53.3 ± 14.1 years. Male patients represented 76% (222) of the sample size, and bilateral cases formed a percentage of 18.8% (Table 1). Pterygium surgery was performed on 94 eyes. In the operated eyes, pterygium was most commonly located on the nasal side (92.6%), and it involved the cornea in 55% of the cases. In the univariate analysis, female gender, age > 70 years and hypertension were associated with corneal involvement (Table 2). However, in the multivariate regression analysis, female gender was the only independent risk factor (Table 3).

Recurrence

The overall rate of recurrence was 17% along a mean follow-up period of 29.3 ± 11.9 months, and a median of 31 months. None of the operated patients older than 70 years developed recurrence. Young age, that is, less than 50 years, was associated with a nonsignificantly higher risk of recurrence (adjusted OR= 1.4, p = 0.528) (Table 4).

| Table 1 Clinical features of patients presenting with pterygium |
|-----------------------------------------------|
| Characteristics                      | n = 292 |
| Age groups                         |        |
| < 50                              | 123 (42.1%) |
| 50−70                             | 134 (45.9%) |
| > 70                              | 35 (12%) |
| Mean age (years)                  | 53.32 ± 14.12 |
| Median age (years)                | 53 |
| Age range (years)                 | 18−92 |
| Gender                            |        |
| Male                              | 222 (76%) |
| Female                            | 70 (24%) |
| BMI                               |        |
| Underweight                       | 4 (1.4%) |
| Normal                            | 75 (25.7%) |
| Overweight                        | 102 (34.9%) |
| Obese                             | 111 (38%) |
| Mean BMI ±SD                      | 28.81 ± 5.48 |
| Smoking Status                    |        |
| Nonsmoker                         | 270 (92.5%) |
| Smoker                            | 22 (7.5%) |
| Ophthalmic Characteristics         |        |
| Eye Involvement                   |        |
| Unilateral                        | 237 (81.2%) |
| Bilateral                         | 55 (18.8%) |
| Dryness                           | 86 (29.5%) |
| Systemic Comorbidities            |        |
| Diabetes mellitus                 | 88 (30.1%) |
| Hypertension                      | 100 (34.2%) |
| Dyslipidemia                      | 127 (43.5%) |
| Treatment Options                 |        |
| Observation                       | 198 (67.8%) |
| Surgery                           | Overall operated cases |
| CAG                               | 94 (32.2%) |
| CAG + MMC 0.02 %                  | 19 (20.2) |
| AMG                               | 64 (68.1) |
| AMG                               | 11 (11.7) |

BMI Body mass index, CAG Conjunctival autograft, MMC Mitomycin C, AMG Amniotic membrane graft
Dry eye disease was a factor associated with an increased rate of recurrence in both univariate and multivariate analyses (Tables 4 and 5). Preoperative pterygium corneal involvement was not associated with a statistically significant increase in the recurrence rate \((p = 0.091)\) in univariate analysis. Age and gender were not associated with a significant risk of recurrence in univariate analysis. Recurrence occurred in 16 eyes (17 %), with an average time of 14.2 ± 11.9 months (Table 6). The 12-month overall average recurrence rate was 10.6 %. The recurrence rates following conjunctival autografting with and without mitomycin C were 15.6 and 15.8 %, respectively. The additional use of intraoperative mitomycin C 0.02 % combined with a conjunctival autograft did not lower the recurrence rates \((p = 0.986)\). The recurrence rate following the amniotic membrane graft was twofold (OR = 2.02) (27 %) that following the conjunctival autograft (15.8 %). There was no statistically significant difference between the three surgical interventions \((p = 0.453)\). In the survival analysis, there was no statistically significant difference in recurrence time between the three surgical procedures \((p = 0.479)\) (Table 7). The addition of fibrin glue to Vicryl sutures did not lower the risk of recurrence (Table 8).

**Discussion**

This is the first study Saudi Arabia to describe the characteristics and recurrence of different surgical methods over a long follow-up period. We found that pterygium was most commonly located on the nasal side. Different theories surround the tendency of pterygium to occur nasally. First, the protective effect of the nose may protect the temporal side against UV light shining nasally \([17, 18]\). Second, dust particles flowing nasally into the nasolacrimal duct may cause mechanical irritation \([17, 19]\). Finally, it has been proposed that forehead perspiration with lactic acid contained in sweat falling from the forehead downside the nose into the nasal conjunctiva may trigger biochemical irritation \([17]\). Pterygium was found to be most common in people between 50 and 70 years old. Multiple studies have found that age greater than 50 years is a risk factor \([7, 20, 21]\). It is expected that increasing age increases people’s exposure to UV radiation. In our study, pterygium was found to be more common among males. This might be due to differences between the two genders in Saudi Arabia in terms of time spent outdoors. Studies in South Korea found that

**Table 2** Predictors of pterygium severity (based on corneal involvement) \((n=94)\)

| Factor             | Cornea spared | Cornea involved | \(\beta\) | OR       | 95% CI        | \(P\)-value |
|--------------------|---------------|-----------------|-----------|-----------|---------------|-------------|
| Gender             |               |                 |           |           |               |             |
| Male               | 37 (88.1)     | 33 (63.5)       |           | 1         |               |             |
| Female             | 5 (11.9)      | 19 (36.5)       | 1.449     | 4.261     | 1.431-12.687  | 0.009       |
| Age groups         |               |                 |           |           |               |             |
| <50                | 22 (52.4)     | 16 (30.8)       |           | 1         |               |             |
| 50-70              | 17 (40.5)     | 25 (48.1)       | 0.704     | 2.022     | 0.829-4.930   | 0.122       |
| >70                | 3 (7.1)       | 11 (21.2)       | 1.618     | 5.042     | 1.207-21.064  | 0.027       |
| Smoking status     |               |                 |           |           |               |             |
| Non-smoker         | 36 (85.7)     | 59 (96.2)       |           | 1         |               |             |
| Smoker             | 6 (14.3)      | 2 (3.8)         | -1.427    | 0.240     | 0.046-1258    | 0.091       |
| BMI                |               |                 |           |           |               |             |
| Underweight        | 1 (2.4)       | 2 (3.8)         |           | 1         |               |             |
| Normal             | 14 (33.3)     | 13 (25)         | -0.767    | 0.464     | 0.037-5.749   | 0.550       |
| Overweight         | 17 (40.5)     | 16 (30.8)       | 0.754     | 0.471     | 0.039-5.708   | 0.554       |
| Obese              | 10 (23.8)     | 21 (40.4)       | 0.049     | 1.050     | 0.085-12.995  | 0.970       |
| Unilateral eye involvement | 37 (88.1) | 48 (92.3) | 0.483 | 1.622 | 0.407-6.465 | 0.493 |
| Dry eye disease    | 11 (26.2)     | 9 (17.3)        | -5.28     | 0.590     | 0.218-1.595   | 0.298       |
| Diabetes mellitus  | 12 (28.6)     | 19 (36.5)       | 0.369     | 1.439     | 0.600-3.455   | 0.415       |
| Dyslipidemia       | 16 (38.1)     | 21 (40.4)       | 0.096     | 1.101     | 0.478-2.533   | 0.821       |
| Hypertension       | 10 (23.8)     | 24 (46.2)       | 1.009     | 2.743     | 1.120-6.714   | 0.027       |
| Location           |               |                 |           |           |               |             |
| Nasal              | 37 (88.1)     | 50 (96.2)       |           | 1         |               |             |
| Temporal           | 5 (11.9)      | 2 (3.8)         | -1.217    | 0.296     | 0.054-1.611   | 0.159       |

**Table 3** Multivariate analysis of greater pterygium severity

| Factors  | \(\beta\) | Adjusted OR | 95% CI | \(P\)-value |
|----------|-----------|-------------|--------|-------------|
| Age < 50 | 1         |             |        |             |
| 50-70    | 0.258     | 1.295       | 0.471-3.560 | 0.567     |
| > 70     | 0.856     | 2.354       | 0.485-11.435 | 0.617    |
| Hypertension | Yes | 0.475     | 2.337 | 0.845-6.462 | 0.102     |
| Gender   |           |             |        |             |
| Male     | 1         |             |        |             |
| Female   | 1.273     | 3.572       | 1.125-11.339 | 0.031    |
male gender was a risk factor [21]. In Indonesia, there was no difference between males and females in developing pterygium [22]. Notably, only 7.5% of our patients were current smokers. Meta-analytical studies have identified smoking as a protective factor against pterygium [7, 23]. The underlying molecular protective mechanisms of smoking are unknown. In the present study, the rate of bilateral pterygium was 18.8%. This is close to the rate reported in Inner Mongolia, which was 24.2% [20]. The only published study about pterygium in Saudi Arabia reported a higher rate of bilateral pterygium (46%), probably because only advanced pterygia were included in that study [8].

Corneal involvement was observed in 55% of the operated eyes. Previous studies have shown that pterygium causes not only astigmatism but also high-order aberrations with larger pterygia [24, 25]. In our study, the only independent risk factor for corneal involvement was female gender. Tan et al. developed a grading system based on the clarity of blood vessels and eventually found that it is a risk factor for recurrence following bare scleral excision [26]. Most previous studies graded pterygia based on their morphological appearance and not on their anatomical extension [22, 26–28]. Studies on pterygium severity, based on pterygium blood-vessel clarity, found that the only risk factor for greater severity was sun exposure for more than 5 h per day [27]. In another study, male gender and outdoor activities were found to be risk factors for fleshy pterygium [28]. In our study, we graded pterygium anatomically, and corneal involvement was not found to be associated with a significant risk of pterygium recurrence. A previous study showed that corneal involvement increased pterygium recurrence; however, the sample was limited to only male patients undergoing bare sclera excision with intraoperative mitomycin C 0.02% [29].

In the present study, none of the patients older than 70 years (14 patients) developed any recurrence. In multiple studies, young age was shown to be a risk factor for recurrence after a limbal conjunctival autograft [30, 31]. In a similar manner to what we observed, patients under the age of 54 years were found to have a higher rate of recurrence following conjunctival autografting, albeit this difference was not statistically significant [32]. This finding can be explained by the fact that aging slows and delays the wound healing process [33]. In other studies,

| Factors       | Total Number | Recurrence (%) | β   | OR    | 95% CI  | P-value |
|---------------|--------------|----------------|-----|-------|---------|---------|
| Age Under 50  | 38           | 8 (21.1)       | 0.470 | 1.6   | 0.543–4.716 | 0.394   |
| Above 50      | 56           | 8 (14.3)       | 1   |       |         |         |
| Gender Female | 24           | 4 (16.7)       | -0.034 | 0.967 | 0.280–3.342 | 0.957   |
| Male          | 70           | 12 (17.1)      | 1   |       |         |         |
| Smoking       | 8            | 1 (12.5)       | -0.391 | 0.676 | 0.077–5.911 | 0.724   |
| BM1 Underweight | 3         | 0              | -20.147 | 0 | 0        | 0.999 |
| Normal        | 27           | 3 (18.8)       | -1.023 | 0.359 | 0.085–1.524 | 0.165   |
| Overweight    | 33           | 5 (31.3)       | -0.667 | 0.513 | 0.148–1.785 | 0.294   |
| Obese         | 31           | 8 (26.2)       | 1   |       |         |         |
| Bilaterality  | 9            | 3 (18.8)       | 1.019 | 2.769 | 0.614–12.492 | 0.185 |
| Dry eye disease | 20      | 7 (35)         | 1.358 | 3.889 | 1.227–12.323 | 0.021   |
| Diabetes mellitus | 31   | 7 (22.6)     | 0.560 | 1.750 | 0.538–5.250 | 0.318   |
| Dyslipidemia  | 37           | 9 (24.3)       | 0.831 | 2.296 | 0.771–6.833 | 0.135   |
| Hypertension  | 34           | 7 (20.6)       | 0.385 | 1.469 | 0.493–4.380 | 0.49    |
| Severity      | 52           | 12 (23.1)      | 1.047 | 2.850 | 0.845–9.611 | 0.091   |
| Location Temporal | 7    | 1 (14.3)   | -0.223 | 0.800 | 0.090–7.140 | 0.842   |
| Nasal         | 87           | 15 (17.2)      | 1   |       |         |         |

**Table 5** Multivariate analysis of predictors recurrence

| Factor       | β   | Adjusted OR | 95% CI  | P-value |
|--------------|-----|-------------|---------|---------|
| Age Above 50 | 0.360 | 1.433       | 0.468–1.433 | 0.528   |
| Dry eye disease | 1.321 | 3.748       | 1.174–11.961 | 0.026   |

**Table 6** Details of overall recurrence rate

| Recurrence Rate | Recurrence before the first year | Recurrence after the first year | Mean time of recurrence in months | Median of time of recurrence in months | Range of time of recurrence in months |
|----------------|---------------------------------|---------------------------------|----------------------------------|----------------------------------------|--------------------------------------|
| Overall postoperative recurrence | 16 (17%)            | 10 (62.5)                       | 6 (37.5)                         | 14.19 ± 11.90                          | 2–40                                 |
| Recurrence before the first year | 10 (62.5)           |                                 | 6 (37.5)                         |                                        |                                      |
| Recurrence after the first year |                                 | 6 (37.5)                        |                                 |                                        |                                      |
| Mean time of recurrence in months | 14.19 ± 11.90 |                                 |                                 |                                        |                                      |
| Median of time of recurrence in months | 14.19 ± 11.90 |                                 |                                 |                                        |                                      |
| Range of time of recurrence in months | 2–40            |                                 |                                 |                                        |                                      |
OSMOSIS 12 months after recurrence [41]. was also found to increase dryness and decrease the tear recurrence [40]. On the other hand, pterygium recurrence to topical steroids in reducing the rate of pterygium re-

Additionally, artificial tears provided additional benefit helpful for decreasing these proinflammatory cytokines. MMP-9 are expressed in advanced pterygia [37]. Interleukin-6 (IL-6), which is elevated in patients with dry eye disease [35]. Yang et al. found that MMP-2 and MMP-9 is a useful bio-

marker in the diagnosis and follow-up of patients with dry eye disease [35]. In fact, it has been suggested that MMP-9 is a useful biomarker in the diagnosis and follow-up of patients with dry eye disease [35]. Yang et al. found that MMP-2 and MMP-9 are expressed in advanced pterygia [37]. Interleukin-6 (IL-6), which is elevated in patients with dry eye disease, was also shown to be significantly higher in cases of recurrent pterygium compared to primary pterygium [38, 39]. Frequent postoperative lubrication is helpful for decreasing these proinflammatory cytokines. Additionally, artificial tears provided additional benefit to topical steroids in reducing the rate of pterygium recur-

ence [40]. On the other hand, pterygium recurrence was also found to increase dryness and decrease the tear osmolarity 12 months after recurrence [41].

Recurrence remains a challenging problem in pterygium management. The overall recurrence rate in our study was found to be 17 %, with an average time of 14 ± 11.9 months, with 37 % of cases occurring after the first year. This stresses the importance of long-term follow-up after pterygium excision. With regards to conjunctival autografting, a procedure first described Kenyon et al. in 1998 [2], recurrence was noted in the present study in 15.8 % of the cases. This is close to what has been shown by Huerva et al., who reported a recurrence rate of 11.76 % over an average follow-up time of 49 months [42]. In a study with a similar mean follow-up period (34 months) to that in our study (29 months), recurrence occurred in 11.4 % of cases [43]. In another study on conjunctival autografts, recurrence was observed in 4 cases (rate of 8 %), with an average time of recurrence of 4.5 months [32]. We as-

sume that we demonstrated a higher recurrence rate in our study due to geographical differences. Our study was conducted in Riyadh, a city for its dry and dusty weather conditions, which is a risk factor for pterygium development and may be responsible for raising the risk of recurrence. Moreover, our rate was higher possibly because we had an extended follow-up period. Another study showed a low rate of recurrence (10 %) because of the short-term follow-up (14 months) [44]. As a general overview, the recurrence rate following conjunctival autografting ranged from 5 to 39 % [9, 42, 44-48]. The variation in recurrence rates is mainly due to differences in follow-up periods, study populations and areas. Not only is this point salient, but surgical skills and experience may also play a role in the fluctuation of recurrence rates. Previous experience with conjunctival autograft procedures was significantly associated with lower recurrence [46]. The mean overall recurrence rate over 12 months in a recent study on primary closure, conjunctival autografts, and amniotic membrane transplantation was 11.3 % [49]. This is similar to the 12-month overall rate of recurrence in the present study, which was 10.6 %. Similar rates of recurrence were observed in the present study between conjunctival autografts with and without mitomycin C. Similarly, in a retrospective observational study, mitomi-

ycin C.04 % for 2 min did not lower the risk of recurrence [31]. In a study on conjunctival autografts combined with mitomycin C, the recurrence rate was 3.6 % [50]. However, the study was only conducted on 28 patients over 12 months, which may have underestimated the recurrence

| Surgical procedure                  | Total number of cases | Recurrence (%) | β    | OR    | 95% CI | p-value | Mean time of recurrence in months ± SD | 95% CI | p-value |
|-------------------------------------|-----------------------|----------------|------|-------|--------|---------|---------------------------------------|--------|---------|
| Conjunctival autograft              | 19                    | 3 (15.8)       | 1    |       |        |         | 8.67 ± 3.33                           | 2.13-15.2 | 0.479   |
| Conjunctival autograft + MMC        | 64                    | 10 (15.6)      | 0.012| 0.988 | 0.242-4.028 | 0.986   | 13.5 ± 3.83                           | 5.99-21.01 | 0.012   |
| Amniotic membrane transplant       | 11                    | 3 (27.3)       | 0.693| 2.02  | 0.472-8.634 | 0.453   | 22 ± 8.72                            | 4.91-39.09 | 0.003   |

| Table 7 Recurrence after each surgical procedure |

| Procedure (n= 92) | Conjunctival Autograft (n=18) | Conjunctival with MMC (n=63) | Amniotic membrane transplant (n=11) |
|-------------------|--------------------------------|-------------------------------|-------------------------------------|
|                   | Recurrence (%) | Survival analysis | Recurrence (%) | Survival analysis | Recurrence (%) | Survival analysis |
|                   | Mean±SD (months) | P | Mean±SD (months) | P | Mean±SD (months) | P |
| Sutures alone (n= 62) | 2 (20) | 0.671 | 7 ±5 | 0–16.8 | 0.405 | 6 (14) | 0.541 | 16.33±5.92 | 4.73-27.94 | 0.872 | 3 (33.3) | 0.338 | 22±8.72 | 4.91-39.09 | NA |
| Suture + fibrin (n= 30) | 1 (12.5) | 12 | 12 | 4 (20) | 9.25±3.54 | 2.30-16.19 | 0 (0) | 0 | |

2 patients underwent closure by fibrin alone and had no recurrence
rate. In a larger retrospective Japanese study, the recurrence rate after conjunctival autografting with intraoperative mitomycin C was 3.96%; however, the follow-up time was only 9 months [48]. In the present study, recurrence following conjunctival grafting with intraoperative mitomycin C developed in an average time of 13.5 months. Fibrin glue was occasionally added to Vicryl sutures to improve patients’ postoperative comfort and reduce graft-related complications [51]. In two meta-analytical studies, a lower recurrence was noted with fibrin glue than with sutures [52, 53]. When fibrin glue was added to sutures in our study, the recurrence rate was similar with no statistically significant difference. In a recent study on pterygium recurrence, patients were divided into 3 groups: fibrin glue combined with conjunctival sutures, fibrin glue alone and sutures alone. The study did not show a statistically significant difference between the three groups [51]. However, the number of recurrences was too small to find any differences. More studies are needed to confirm whether fibrin glue applied over Vicryl sutures can reduce pterygium recurrence.

The amniotic membrane promotes conjunctival epithelialization and inhibits fibroblasts [54]. The advantages of amniotic membranes include short postoperative visual recovery, better comfort and less operation time [55]. Moreover, the amniotic membrane may cover a large area of the defect or be utilized when conjunctival scarring exists, which prevents sufficient autografting. In the present study, recurrence was higher in the amniotic membrane (OR= 2.02) (27 %) than in the conjunctival graft (15.8 %) of the cases treated with an amniotic membrane graft. The range of recurrence rates following amniotic membrane grafts reported in the literature ranges from 14.5 to 41.7 % [55–60]. In a study comparing conjunctival autografts with amniotic membrane grafts, the rates of recurrence were 13.1 and 28.1 %, respectively, over 6 months [61]. Our study identified similar recurrence rates, but the difference was not statistically significant because of the relatively low number of amniotic membrane grafts.

Because of the retrospective nature of the study, it was difficult to report the exact sizing and morphological description of the lesions. Also, data on pterygium severity was available only for patients who underwent surgical excision and missing for patients who did not undergo excision. Since all our patients share the same race, it was not possible to analyze whether race is a risk factor for recurrence. Long-term multicenter prospective studies on pterygium recurrence are required to analyze risk factors for recurrence. The present study did not include a healthy control group, which prevented us from calculating the risk factors and prevalence rate of pterygium; however, this was not part of the objectives of the study. Future studies on pterygium recurrence may be conducted by one surgeon to control for surgical experience factors.

Conclusions
In conclusion, the only factor associated with the recurrence of pterygium was dry eye disease. More than one-third of recurrences developed after the first year, which stresses the importance of long follow-up. The recurrence in our study following conjunctival graft was slightly higher compared to the literature mainly due to differences in study area, population and follow-up periods. Our study identified similar recurrence rates following conjunctival autografting with versus without mitomycin C. Nevertheless, the recurrence rate following amniotic membrane grafting was twofold that following conjunctival autografting. However, the difference was not statistically significant because of the relatively lower number of patients who underwent amniotic membrane transplantation.

Abbreviations
UV: Ultraviolet; CI: Confidence interval; BMI: Body mass index; MMP: Matrix metalloproteinase

Acknowledgements
None.

Authors’ contributions
WA drafted the manuscript. SA participated in the design of the study, conducted the statistical analysis and drafted the manuscript. MS reviewed the final manuscript critically. NA, OA and AAlm participated in data collection and preparing the manuscript. AAlIs participated in drafting the manuscript. AAll were involved in the diagnosis and management of the patients and preparing the manuscript. BA reviewed the final manuscript critically. The author(s) read and approved the final manuscript.

Funding
None.

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
This study was approved by the Institutional Review Board at King Abdullah International Medical Research Center (KAIMRC). All methods were carried out in accordance with relevant guidelines and regulations. The need for written informed consent was waived by the Institutional Review Board at KAIMRC because of the retrospective design of the study and the use of deidentified patient data.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada. 2Department of Ophthalmology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia. 3College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia. 4Department of Ophthalmology, Faculty of Medicine, King
Abdulaziz University, Jeddah, Saudi Arabia. 3College of Medicine, King Saud University, Riyadh, Saudi Arabia. 4Department of Ophthalmology, Ministry of the National Guard – Health Affairs, Riyadh, Saudi Arabia. 5King Abdullah International Medical Research Center, Riyadh, Saudi Arabia. 6Cornea, Anterior Segment and Refractive Surgery Department, University of Ottawa Eye Institute, Ottawa, Ontario, Canada.

Received: 30 January 2021 Accepted: 22 April 2021
Published online: 11 May 2021

References

1. Coster D. Pterygium—an ophthalmic enigma. Br J Ophthalmol. 1995;79(4):304–5.
2. Kenyon KR, Wagoner MD, Hettinger ME. Conjunctival autograft transplantation for advanced and recurrent pterygium. Ophthalmology. 1985;92(11):1461–70.
3. Balci M, Sahin S, Mutlu FM, Yadig R, Karanci P, Yildiz M. Investigation of oxidative stress in pterygium tissue. Mol Vis. 2011;17:443–7.
4. Bradley JC, Yang W, Bradley RH, Reid TW, Schwab IR. The science of pterygia. Br J Ophthalmol. 2010;94(7):815–20.
5. Liu L, Wu J, Geng J, Yuan Z, Huang D. Geographical prevalence and risk factors for pterygium: a systematic review and meta-analysis. BMJ Open. 2013;3(11):e003787.
6. Ang LP, Chua JL, Tan DT. Current concepts and techniques in pterygium treatment. Curr Opin Ophthalmol. 2007;18(4):308–13.
7. Rezvan F, Khabazkhoob M, Hooshmand E, Yekta A, Saatchi M, Hashemi H. Prevalence and risk factors of pterygium: a systematic review and meta-analysis. Surv Ophthalmol. 2018;63(5):719–35.
8. Alqathani J. The prevalence of pterygium in Al-Khobar: A hospital-based study. Journal of Family and Community Medicine. 2013;20(3):159–61.
9. Chen PP, Aiyarayu RG, Kaza V, Labree ED, McDonnell PJ. A randomized trial comparing mitomycin C and conjunctival autograft after excision of primary pterygium. Am J Ophthalmol. 1995;120(2):151–60.
10. Qin XJ, Chen HM, Guo L, Guo YY. Low-dose strontium-90 irradiation is effective in preventing the recurrence of pterygia: a ten-year study. PLoS One. 2012;7(8):e43500.
11. Narsis N, Fanahangie S, Rahnavard M, Rahmani L, Narsiri N. Corneal endothelial cell injury induced by mitomycin-C in photorefractive keractomyotomy: nonrandomized controlled trial. J Cataract Refract Surg. 2008;34(6):902–8.
12. Avisor R, Avisor I, Babar I, Weinberger D. Effect of mitomycin C in pterygium surgery on corneal endothelium. Cornea. 2008;27(7):559–61.
13. Lindquist TP, Lee WB. Mitomycin C-associated scleral stromal injury after pterygium surgery. Cornea. 2015;34(4):398–401.
14. Campagna G, Adams M, Wang L, Khandelwal S, Al-Mohtaseb Z. Comparison of Pterygium Recurrence Rates Among Different Races and Ethnicities After Primary Pterygium Excision by Surgeons in Training. Cornea. 2018;37(2):199–204.
15. Macdonald FD, Frist LW, Battistutta D, Green A. Risk analysis in the development of pterygia. Ophthalmologica. 1992;200(3):1056–61.
16. Modelesne A, Gobba F. Occupational Exposure to Solar Radiation at Different Latitudes and Pterygium: A Systematic Review of the Last 10 Years of Scientific Literature. Int J Environ Res Public Health. 2017;15(11):3177.
17. Cornejo MT. Pterygium as an early indicator of ultraviolet insulation: a hypothesis. Br J Ophthalmol. 1993;77(1):734–9.
18. Yanoff M, Duker J. Ophthalmology. 6th edition. Philadelphia: Elsevier; 2018.
19. Elliott RH. Tropical Ophthalmology. London: Oxford Medical Publications; 1920.
20. Yanoff M, Duker J. Ophthalmology. 5th. Philadelphia: Elsevier; 2018.

21. Mohammad-Salih PA, Sharif AF. Analysis of pterygium size and induced corneal astigmatism. Cornea. 2008;27(4):434–8.
22. Tan DT, Chee SP, Dear KB, Lim AS. Effect of pterygium morphology on pterygium recurrence in a controlled trial comparing conjunctival autografting with bare sclera excision. Arch Ophthalmol. 1997;115(10):1235–40.
23. Rim TH, Nam J, Kim EK, Kim TI. Risk factors associated with pterygium and its subtypes in Korea: the Korean National Health and Nutrition Examination Survey 2008–2010. Cornea. 2013;32(7):962–70.
24. Ang M, Li X, Wong W, Zheng Y, Chua D, Rahman A, et al. Prevalence of and racial differences in pterygium: a multiethnic population study in Asians. Ophthalmology. 2012;119(8):1505–10.
25. Mahran PS, Manzur N. Pterygium recurrence related to its size and corneal involvement. J Coll Physicians Surg Pak. 2013;23(2):120–3.
26. Aidenloo NS, Motarjemizadeh Q, Heidarpanah M. Risk factors for pterygium recurrence after limbal-conjunctival autografting: a retrospective, single-centre investigation. Jpn J Ophthalmol. 2018;62(3):349–56.
27. Kwon SH, Kim HK. Analysis of recurrence patterns following pterygium surgery with conjunctival autografts. Medicine (Baltimore). 2015;94(4):e1518.
28. Xocamis O, Bligec M. Evaluation of the recurrence rate for pterygium treated with conjunctival autograft. Graefes Arch Clin Exp Ophthalmol. 2014;252(5):817–20.
29. Gosain A, DiPietro LA. Aging and wound healing. World J Surg. 2004;28(3):321–6.
30. Han SB, Jeon HS, Kim M, Lee SJ, Yang HK, Hwang JM, et al. Risk Factors for Recurrence After Pterygium Surgery: An Image Analysis Study. Cornea. 2016;35(8):1097–103.
31. Chotikavanich S, de Paiva CS, Li de Q, Chen JJ, Bian F, Farley WJ, et al. Production and activity of matrix metalloproteinase-9 on the ocular surface increase in dysfunctional tear syndrome. Invest Ophthalmol Vis Sci. 2009;50(7):3203–9.
32. Luo L, Li DQ, Doshi A, Farley W, Corales RM, Pflugfelder SC. Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface. Invest Ophthalmol Vis Sci. 2004;45(12):4293–301.
33. Yang SF, Lin CY, Yang PY, Chao SC, Ye YZ, Hu DN. Increased expression of gelatinase (MMP-2 and MMP-9) in pterygia and pterygium fibroblasts with disease progression and activation of protein kinase C. Invest Ophthalmol Vis Sci. 2009;50(10):4588–96.
34. Yoon KC, Jeong Y, Park YG, Yang SY. Interleukin-6 and tumor necrosis factor-alpha levels in tears of patients with dry eye syndrome. Cornea. 2007;26(4):431–7.
35. Van Acker SI, Haagdorens M, Roelant E, Rozena J, Possemiers T, van Gentven V, et al. Pterygium Pathology: A Prospective Case-Control Study on Tear Film Cytokine Levels. Mediators Inflamm. 2019;2019:9416262.
36. Kampitak K, Leelawongtawan W, Leemarnoria S, Suphachearaparn W. Role of artificial tears in reducing the recurrence of pterygium after surgery: a prospective randomized controlled trial. Acta Ophthalmol. 2017;95(3):e227-e9.
37. Türkyılmaz K, Öner V, Sevîm M, Kurt A, Sekenbayan B, Durmush M. Effect of pterygium surgery on tear osmolarity. J Ophthalmol. 2013;2013:865498.
38. Huerva V, March A, Martinez-Alonso M, Muniesa MJ, Sanchez C. Pterygium surgery by means of conjunctival autograft: long term follow-up. Arq Bras Oftalmol. 2012;75(4):251–5.
39. Varsano D, Shalev H, Lazar M, Fischer N. Pterygium excision with conjunctival autograft: true survival rate statistics. Cornea. 2013;32(9):1243–50.
40. Kmih N, Kamoun B, Trigui A, Jelliti B, Fourati M, Chebelouni M. Effectiveness of conjunctival autograft transplantation in pterygium surgery. J Fr Ophthalmol. 2001;24(7):729–32.
41. Allan BD, Short P, Crawford GJ, Barnett GO, Constable II. Pterygium excision with conjunctival autografting: an effective and safe technique. Br J Ophthalmol. 1993;77(11):698–701.
42. Ti SE, Chee SP, Dear KB, Tan DT. Analysis of variation in success rates in conjunctival autografting for primary and recurrent pterygium. Br J Ophthalmol. 2000;84(4):385–9.
43. Cheddadaron W, Wattananasri S. Conjunctival autograft transplantation for primary pterygium. J Med Assoc Thai. 2000;83(4):729–32.
44. Masuda A, Takahashi K, Nejima R, Minami K, Miyata K. Pterygium excision using bulbar conjunctival autograft with intraoperative mitomycin C for primary pterygium: a retrospective assessment of 1832 eyes. Nippon Ganka Gakkai Zasshi. 2013;117(9):743–8.
49. Röck T, Bramkamp M, Bartz-Schmidt KU, Röck D. A Retrospective Study to Compare the Recurrence Rate After Treatment of Pterygium by Conjunctival Autograft, Primary Closure, and Amniotic Membrane Transplantation. Med Sci Monit. 2019;25:7976–81.

50. Shehadeh-Mashor R, Srinivasan S, Bolmer C, Lee K, Tomkins O, Stornovic AR. Management of recurrent pterygium with intraoperative mitomycin C and conjunctival autograft with fibrin glue. Am J Ophthalmol. 2011;152(5):730–2.

51. Huang X, Zhu B, Lin L, Jin X. Clinical results for combination of fibrin glue and nasal margin suture fixation for attaching conjunctival autografts after pterygium excision in Chinese pterygium patients. Medicine (Baltimore). 2018;97(44):e13050.

52. Pan HW, Zhong JX, Jing CX. Comparison of fibrin glue versus suture for conjunctival autografting in pterygium surgery: a meta-analysis. Ophthalmology. 2011;118(6):1049–54.

53. Lan A, Xiao F, Wang Y, Luo Z, Cao Q. Efficacy of fibrin glue versus sutures for attaching conjunctival autografts in pterygium surgery: a systematic review with meta-analysis and trial sequential analysis of evidence. Oncotarget. 2017;8(25):41487–97.

54. Tseng SC, Espana EM, Kawakita T, Di Pasquaile MA, Li W, He H, et al. How does amniotic membrane work? Ocul Surf. 2004;2(3):177–87.

55. Tananuvat N, Martin T. The results of amniotic membrane transplantation for primary pterygium compared with conjunctival autograft. Cornea. 2004;23(5):458–63.

56. Kuma SA, Altun A, Aksoy B, Kuma R, Sengor T. Comparing Treatment Options of Pterygium: Limbal Sliding Flap Transplantation, Primary Closing, and Amniotic Membrane Grafting. Eur J Ophthal. 2013;23(4):480–7.

57. Liang W, Li R, Deng X. Comparison of the efficacy of pterygium resection combined with conjunctival autograft versus pterygium resection combined with amniotic membrane transplantation. Eye Sci. 2012;27(2):102–5.

58. Song YW, Yu AH, Cai XJ. Effectiveness of amniotic membrane transplantation combined with mitomycin C in the treatment of pterygium: a meta-analysis. Int J Ophthal. 2010;3(4):352–5.

59. Yu C, Liang W, Huang Y, Guan W. Comparison of clinical efficacy of three surgical methods in the treatment of pterygium. Eye Sci. 2011;26(4):193–6.

60. Ozkurt YB, Kocams O, Gomez AT, Uslu B, Dogan OK. Treatment of primary pterygium. Optom Vis Sci. 2009;86(10):1178–81.

61. Luanratanakorn P, Ratanaapakorn T, Suan-Apichon O, Chuck RS. Randomised controlled study of conjunctival autograft versus amniotic membrane graft in pterygium excision. Br J Ophthalmol. 2006;90(12):1476–80.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.